Bayer's Canesten Switched From Rx-To-OTC Status In Poland
Poland's drug regulator, URPL, has switched Bayer's Canesten vaginal yeast infection treatment from prescription-to-OTC status. It is the regulator's fourth switch in 2019 alone.
You may also be interested in...
Having received the green light for its prescription-to-OTC switch, Bayer is launching in UK pharmacies Clarinaze Allergy Control backed by a £1m marketing campaign.
Trend of pharmacy closures in 2018 threatens Polish consumers' access to consumer health products, insists local OTC association PASMI. Over 90% of OTC sales in Poland currently go through pharmacies.
Bayer's Consumer Health chief Heiko Schipper is hoping a focus on innovation and a leaner portfolio will help return the business to mid-single-digit growth by 2022. The German firm has identified its North American business as the 'key area to fix'.